Nicolas Vignon-Zellweger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicolas Vignon-Zellweger has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Noriaki Emoto
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
9 shared publications - Kazuhiko Nakayama
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan
8 shared publications - Keiko Yagi
Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe, Japan
8 shared publications - Susi Heiden
Department of Clinical Pharmacy, Kobe Pharmaceutical University, Kobe, Japan
8 shared publications - Berthold Hocher
Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg
7 shared publications Ken-Ichi Hirata
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicie, Kobe, Japan
7 shared publications
Latest Publications
- Open Access
- 11 November 2016
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 41 (6) , 770-780
Global Overexpression of ET-1 Decreases Blood Pressure - A Systematic Review and Meta-Analysis of ET-1 Transgenic Mice
Background/Aims: ET-1 has independent effects on blood pressure regulation in vivo, it is involved in tubular water and salt excretion, promotes constriction of smooth muscle cells, modulates sympathetic nerve activity, and activates the liberation of nitric oxide. To determine the net effect of these partially counteracting mechanisms on blood pressure, a systematic meta-analysis was performed. Methods: Based on the principles of Cochrane systematic reviews, we searched in major literature databases - MEDLINE (PubMed), Embase, Google Scholar, and the China Biological Medicine Database (CBM-disc) - for articles relevant to the topic of the blood pressure phenotype of endothelin-1 transgenic (ET-1+/+) mice from January 1, 1988 to March 31, 2016. Review Manager Version 5.0 (Rev-Man 5.0) software was applied for statistical analysis. In total thirteen studies reported blood pressure data. Results: The meta-analysis of blood pressure data showed that homozygous ET-1 transgenic mice (ET-1+/+ mice) had a significantly lower blood pressure as compared to WT mice (mean difference: -2.57 mmHg, 95% CI: -4.98∼ -0.16, P = 0.04), with minimal heterogeneity (P = 0.86). A subgroup analysis of mice older than 6 months revealed that the blood pressure difference between ET-1+/+ mice and WT mice was even more pronounced (mean difference: -6.19 mmHg, 95% CI: -10.76∼ -1.62, P = 0.008), with minimal heterogeneity (P = 0.91). Conclusion: This meta-analysis provides robust evidence that global ET-1 overexpression in mice lowers blood pressure in an age-dependent manner. Older ET-1+/+ mice have a somewhat more pronounced reduction of blood pressure.
- 11 November 2016
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 41 (6) , 770-780
Open AccessGlobal Overexpression of ET-1 Decreases Blood Pressure - A Systematic Review and Meta-Analysis of ET-1 Transgenic Mice
Background/Aims: ET-1 has independent effects on blood pressure regulation in vivo, it is involved in tubular water and salt excretion, promotes constriction of smooth muscle cells, modulates sympathetic nerve activity, and activates the liberation of nitric oxide. To determine the net effect of these partially counteracting mechanisms on blood pressure, a systematic meta-analysis was performed. Methods: Based on the principles of Cochrane systematic reviews, we searched in major literature databases - MEDLINE (PubMed), Embase, Google Scholar, and the China Biological Medicine Database (CBM-disc) - for articles relevant to the topic of the blood pressure phenotype of endothelin-1 transgenic (ET-1+/+) mice from January 1, 1988 to March 31, 2016. Review Manager Version 5.0 (Rev-Man 5.0) software was applied for statistical analysis. In total thirteen studies reported blood pressure data. Results: The meta-analysis of blood pressure data showed that homozygous ET-1 transgenic mice (ET-1+/+ mice) had a significantly lower blood pressure as compared to WT mice (mean difference: -2.57 mmHg, 95% CI: -4.98∼ -0.16, P = 0.04), with minimal heterogeneity (P = 0.86). A subgroup analysis of mice older than 6 months revealed that the blood pressure difference between ET-1+/+ mice and WT mice was even more pronounced (mean difference: -6.19 mmHg, 95% CI: -10.76∼ -1.62, P = 0.008), with minimal heterogeneity (P = 0.91). Conclusion: This meta-analysis provides robust evidence that global ET-1 overexpression in mice lowers blood pressure in an age-dependent manner. Older ET-1+/+ mice have a somewhat more pronounced reduction of blood pressure.
- Open Access
- 1 November 2014
- Published by Elsevier in Life Sciences
- Vol. 118 (2) , 77-86
25Years of endothelin research: the next generation
- 1 November 2014
- Published by Elsevier in Life Sciences
- Vol. 118 (2) , 77-86
Open Access25Years of endothelin research: the next generation
- Open Access
- 1 November 2014
- Published by Elsevier in Life Sciences
- Vol. 118 (2) , 219-225
Endothelin-1 overexpression and endothelial nitric oxide synthase knock-out induce different pathological responses in the heart of male and female mice
- 1 November 2014
- Published by Elsevier in Life Sciences
- Vol. 118 (2) , 219-225
Open AccessEndothelin-1 overexpression and endothelial nitric oxide synthase knock-out induce different pathological responses in the heart of male and female mice
- Open Access
- 1 November 2014
- Published by Elsevier in Life Sciences
- Vol. 118 (2) , 313-328
Inhibition of vascular endothelial growth factor receptor under hypoxia causes severe, human-like pulmonary arterial hypertension in mice: Potential roles of interleukin-6 and endothelin
- 1 November 2014
- Published by Elsevier in Life Sciences
- Vol. 118 (2) , 313-328
Open AccessInhibition of vascular endothelial growth factor receptor under hypoxia causes severe, human-like pulmonary arterial hypertension in mice: Potential roles of interleukin-6 and endothelin
- Open Access
- 11 February 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e88730
Vascular Endothelium Derived Endothelin-1 Is Required for Normal Heart Function after Chronic Pressure Overload in Mice
Endothelin-1 participates in the pathophysiology of heart failure. The reasons for the lack of beneficial effect of endothelin antagonists in heart failure patients remain however speculative. The anti-apoptotic properties of ET-1 on cardiomyocytes could be a reasonable explanation. We therefore hypothesized that blocking the pro-apoptotic TNF-α pathway using pentoxifylline could prevent the deleterious effect of the lack of ET-1 in a model for heart failure. We performed transaortic constriction (TAC) in vascular endothelial cells specific ET-1 deficient (VEETKO) and wild type (WT) mice (n = 5–9) and treated them with pentoxifylline for twelve weeks. TAC induced a cardiac hypertrophy in VEETKO and WT mice but a reduction of fractional shortening could be detected by echocardiography in VEETKO mice only. Cardiomyocyte diameter was significantly increased by TAC in VEETKO mice only. Pentoxifylline treatment prevented cardiac hypertrophy and reduction of fractional shortening in VEETKO mice but decreased fractional shortening in WT mice. Collagen deposition and number of apoptotic cells remained stable between the groups as did TNF-α, caspase-3 and caspase-8 messenger RNA expression levels. TAC surgery enhanced ANP, BNP and bcl2 expression. Pentoxifylline treatment reduced expression levels of BNP, bcl2 and bax. Lack of endothelial ET-1 worsened the impact of TAC-induced pressure overload on cardiac function, indicating the crucial role of ET-1 for normal cardiac function under stress. Moreover, we put in light a TNF-α-independent beneficial effect of pentoxifylline in the VEETKO mice suggesting a therapeutic potential for pentoxifylline in a subpopulation of heart failure patients at higher risk.
- 11 February 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e88730
Open AccessVascular Endothelium Derived Endothelin-1 Is Required for Normal Heart Function after Chronic Pressure Overload in Mice
Endothelin-1 participates in the pathophysiology of heart failure. The reasons for the lack of beneficial effect of endothelin antagonists in heart failure patients remain however speculative. The anti-apoptotic properties of ET-1 on cardiomyocytes could be a reasonable explanation. We therefore hypothesized that blocking the pro-apoptotic TNF-α pathway using pentoxifylline could prevent the deleterious effect of the lack of ET-1 in a model for heart failure. We performed transaortic constriction (TAC) in vascular endothelial cells specific ET-1 deficient (VEETKO) and wild type (WT) mice (n = 5–9) and treated them with pentoxifylline for twelve weeks. TAC induced a cardiac hypertrophy in VEETKO and WT mice but a reduction of fractional shortening could be detected by echocardiography in VEETKO mice only. Cardiomyocyte diameter was significantly increased by TAC in VEETKO mice only. Pentoxifylline treatment prevented cardiac hypertrophy and reduction of fractional shortening in VEETKO mice but decreased fractional shortening in WT mice. Collagen deposition and number of apoptotic cells remained stable between the groups as did TNF-α, caspase-3 and caspase-8 messenger RNA expression levels. TAC surgery enhanced ANP, BNP and bcl2 expression. Pentoxifylline treatment reduced expression levels of BNP, bcl2 and bax. Lack of endothelial ET-1 worsened the impact of TAC-induced pressure overload on cardiac function, indicating the crucial role of ET-1 for normal cardiac function under stress. Moreover, we put in light a TNF-α-independent beneficial effect of pentoxifylline in the VEETKO mice suggesting a therapeutic potential for pentoxifylline in a subpopulation of heart failure patients at higher risk.
- Open Access
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25-26) , e47
Analysis of ET-1 system in mild and severe pulmonary arterial hypertension in mice
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25-26) , e47
Open AccessAnalysis of ET-1 system in mild and severe pulmonary arterial hypertension in mice
- Open Access
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e19
Absence of ETA receptors on podocytes is not antialbuminuric in diabetic mice
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e19
Open AccessAbsence of ETA receptors on podocytes is not antialbuminuric in diabetic mice
- Open Access
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25-26) , e18-e19
Renal phenotype of type 1 diabetic endothelial cell derived ET-1 deficient mice
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25-26) , e18-e19
Open AccessRenal phenotype of type 1 diabetic endothelial cell derived ET-1 deficient mice
- Open Access
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e17
Endothelial cell/INS;-derived endothelin-1 exaggerates kidney fibrosis through ETAR activation in renal interstitial cells
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e17
Open AccessEndothelial cell/INS;-derived endothelin-1 exaggerates kidney fibrosis through ETAR activation in renal interstitial cells
- Open Access
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e16
Endothelin converting enzyme inhibition attenuates early albuminuria and late renal failure in streptozotocin induced diabetic mice
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e16
Open AccessEndothelin converting enzyme inhibition attenuates early albuminuria and late renal failure in streptozotocin induced diabetic mice